Literature DB >> 16880177

Can the Asthma Control Questionnaire be used to differentiate between patients with controlled and uncontrolled asthma symptoms? A pilot study.

Lotte van den Nieuwenhof1, Tjard Schermer, Petra Eysink, Eric Halet, Chris van Weel, Patrick Bindels, Ben Bottema.   

Abstract

BACKGROUND: A substantial number of adult patients with asthma are inadequately controlled despite the availability of effective asthma treatment. Patients and physicians seem to overestimate the level of asthma control.
OBJECTIVE: The current study explores whether valid differentiation is possible between asthma patients with controlled and uncontrolled asthma symptoms, on the basis of the Asthma Control Questionnaire (ACQ).
METHODS: In this multi-centre, cross-sectional study, patients were classified according to Global Initiative for Asthma criteria into levels of asthma symptom control based on a diary card registration. We defined Step 1 ('well controlled' asthma symptoms), Step 2 ('moderately controlled'), Step 3 ('poorly controlled') and Step 4 ('very poorly controlled'). These control steps were related with the sum score of the ACQ.
RESULTS: From 108 asthma patients complete data were obtained. The Step 1 subgroup comprised 17 patients; Step 2, 12 patients; Step 3, 22 patients; and Step 4, 57 patients. Receiver Operating Characteristic curve analysis showed that the optimal ACQ sum score cut-off value to differentiate between Step 1 and Steps 2, 3 and 4 was three points (sensitivity: 84%, specificity: 76%). For Steps 1 and 2 versus Steps 3 and 4, this was four points (sensitivity: 77%, specificity: 59%). For Steps 1, 2 and 3 versus Step 4, this was six points (sensitivity: 70%, specificity: 74%).
CONCLUSION: Our results show that discrimination between asthma patients with controlled and uncontrolled asthma symptoms, based on the ACQ, is possible with a reasonable margin of test inaccuracy. Thus, the ACQ may be an important tool for health care professionals who aim to optimize the level of asthma control in their patient population.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16880177     DOI: 10.1093/fampra/cml041

Source DB:  PubMed          Journal:  Fam Pract        ISSN: 0263-2136            Impact factor:   2.267


  13 in total

1.  Validation of the AQLQ12+ among adolescents and adults with persistent asthma.

Authors:  Kathleen W Wyrwich; Andrea M Ireland; Prakash Navaratnam; Hendrik Nolte; Davis F Gates
Journal:  Qual Life Res       Date:  2010-12-24       Impact factor: 4.147

Review 2.  Asthma outcomes: composite scores of asthma control.

Authors:  Michelle M Cloutier; Michael Schatz; Mario Castro; Noreen Clark; H William Kelly; Rita Mangione-Smith; James Sheller; Christine Sorkness; Stuart Stoloff; Peter Gergen
Journal:  J Allergy Clin Immunol       Date:  2012-03       Impact factor: 10.793

3.  Weekly self-monitoring and treatment adjustment benefit patients with partly controlled and uncontrolled asthma: an analysis of the SMASHING study.

Authors:  Victor van der Meer; Henk F van Stel; Moira J Bakker; Albert C Roldaan; Willem J J Assendelft; Peter J Sterk; Klaus F Rabe; Jacob K Sont
Journal:  Respir Res       Date:  2010-06-10

4.  Tracing uncontrolled asthma in family practice using a mailed asthma control questionnaire.

Authors:  Lotte van den Nieuwenhof; Tjard Schermer; Marianne Heins; Joke Grootens; Petra Eysink; Ben Bottema; Chris van Weel; Patrick Bindels
Journal:  Ann Fam Med       Date:  2008 Jan-Feb       Impact factor: 5.166

5.  Montelukast as an alternative to low-dose inhaled corticosteroids in the management of mild asthma (the SIMPLE trial): an open-label effectiveness trial.

Authors:  R Andrew McIvor; Alan Kaplan; Caroline Koch; John S Sampalis
Journal:  Can Respir J       Date:  2009 May-Jun       Impact factor: 2.409

6.  Montelukast as add-on therapy to inhaled corticosteroids in the management of asthma (the SAS trial).

Authors:  J Mark FitzGerald; Sylvain Foucart; Stephen Coyle; John Sampalis; Denis Haine; Eliofotisti Psaradellis; R Andrew McIvor
Journal:  Can Respir J       Date:  2009 May-Jun       Impact factor: 2.409

7.  Measurement of asthma control according to Global Initiative for Asthma guidelines: a comparison with the Asthma Control Questionnaire.

Authors:  José María Olaguibel; Santiago Quirce; Berta Juliá; Cristina Fernández; Ana María Fortuna; Jesús Molina; Vicente Plaza
Journal:  Respir Res       Date:  2012-06-22

8.  Asthma control cost-utility randomized trial evaluation (ACCURATE): the goals of asthma treatment.

Authors:  Persijn J Honkoop; Rik J B Loymans; Evelien H Termeer; Jiska B Snoeck-Stroband; Moira J Bakker; Willem J J Assendelft; Peter J Sterk; Gerben Ter Riet; Tjard R J Schermer; Jacob K Sont
Journal:  BMC Pulm Med       Date:  2011-11-24       Impact factor: 3.317

9.  Effectiveness of montelukast administered as monotherapy or in combination with inhaled corticosteroid in pediatric patients with uncontrolled asthma: a prospective cohort study.

Authors:  Denis Bérubé; Michel Djandji; John S Sampalis; Allan Becker
Journal:  Allergy Asthma Clin Immunol       Date:  2014-05-06       Impact factor: 3.406

10.  Longitudinal outcomes of different asthma phenotypes in primary care, an observational study.

Authors:  Rishi J Khusial; Jacob K Sont; Rik J B Loijmans; Jiska B Snoeck-Stroband; Pim J J Assendelft; Tjard R J Schermer; Persijn J Honkoop
Journal:  NPJ Prim Care Respir Med       Date:  2017-10-03       Impact factor: 2.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.